Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial

Metabolism: Clinical and Experimental

Volumn 65, Issue 11, 2016, Pages 1636-1645

  Asztalos, Ivor B ^a,b,d   Gleason, Joi A ^a,b   Sever, Sakine ^a   Gedik, Reyhan ^a   Asztalos, Bela F ^b   Horvath, Katalin V ^b   Dansinger, Michael L ^a,b,c   Lamon Fava, Stefania ^b   Schaefer, Ernst J ^a,b  

^a Cardiovascular Research Center   (United States)

^b TUFTS UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Fish oils; Lp PLA2; Omega 3 fatty acids; Triglycerides

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIVE OIL; TRIACYLGLYCEROL; APOLIPOPROTEIN B; CARDIOTONIC AGENT; PHOSPHOLIPASE A2;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET RESTRICTION; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; ERUCTATION; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; YEAST; BLOOD; CARDIOVASCULAR DISEASES; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME;

APOLIPOPROTEINS; APOLIPOPROTEINS B; BIOMARKERS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; OLIVE OIL; PHOSPHOLIPASES A2; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84989843216     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.07.010     Document Type: Article

References (48)

1. [1] Harris, WS, Miller, M, Tighe, AP, Davidson, MH, Schaefer, EJ, Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197 (2008), 12–24.
2. [2] Phillipson, BE, Rothrock, DW, Connor, WE, Harris, WS, Illingworth, DR, Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 312 (1985), 1210–1216.
3. [3] Chan, DC, Watts, GF, Mori, TA, Barrett, PHR, Redgrave, TG, Beilin, LJ, Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr 77 (2003), 300–307.
4. [4] Burr, M, Gilbert, J, Holliday, R, Elwood, P, Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction: diet and reinfarction trial (DART). Lancet 2 (1989), 757–761.
5. [5] GISSI, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999), 447–455.
6. [6] Marchioli, R, Barzi, F, Bomba, E, Chieffo, C, DiGregorio, D, DiMascio, R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della lipid health. Circulation 105 (2002), 1897–1903.
7. [7] Yokoyama, M, Origasa, H, Matsuzaki, M, Matsuzawa, Y, Saito, Y, Ishikawa, Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 (2007), 1090–1098.
8. [8] Matsuzaki, M, Yokoyama, M, Saito, Y, Origas, H, Ishikawa, Y, Oikawa, S, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 73 (2009), 1283–1290.
9. [9] Tanaka, K, Ishikawa, Y, Yokoyama, M, Origasa, H, Matsuzaki, M, Saito, Y, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 39 (2008), 2052–2058.
10. [10] Saito, Y, Yokoyama, M, Origasa, H, Matsuzaki, M, Matsuzawa, Y, Ishikawa, Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200 (2008), 135–140.
11. [11] Itakura, H, Yokoyama, M, Matsuzaki, M, Saito, Y, Origasa, H, Ishikawa, Y, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 18 (2011), 99–107.
12. [12] MacKenzie, SA, Belcher, LA, Sykes, GP, Frame, SR, Mukerji, P, Gillies, PJ, Safety assessment of EPA-rich oil produced from yeast: results of a 90-day subchronic toxicity study. Regul Toxicol Pharmacol 58 (2010), 490–500.
13. [13] Belcher, LA, MacKenzie, SA, Donner, M, Sykes, GP, Frame, SR, Gillies, PJ, Safety assessment of EPA-rich triglyceride oil produced from yeast: genotoxicity and 28-day oral toxicity in rats. Regul Toxicol Pharmacol 59 (2011), 53–63.
14. [14] Otokozawa, S, Ai, M, Asztalos, BF, White, CC, Demissie-Banjaw, S, Cupples, LA, et al. Direct assessment of plasma low density lipoprotein and high density lipoprotein cholesterol levels and coronary heart disease: results from the Framingham offspring study. Atherosclerosis 213 (2010), 251–255.
15. [15] Ai, M, Otokozawa, S, Asztalos, BF, Ito, Y, Nakajima, K, White, CC, et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham offspring study. Clin Chem 56 (2010), 967–976.
16. [16] Ingelsson, E, Schaefer, EJ, Contois, JH, McNamara, JR, Sullivan, L, Keyes, MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 (2007), 776–785.
17. [17] Jenner, JL, Seman, LJ, Millar, JS, Lamon-Fava, S, Welty, FK, Dolnikowski, GG, et al. The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism 54 (2005), 361–369.
18. 2 in patients with coronary heart disease versus control subjects. Am J Cardiol 95 (2005), 1025–1032.
19. [19] Otokozawa, S, Ai, M, Diffenderfer, MR, Asztalos, BF, Tanaka, A, Lamon-Fava, S, et al. Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects. Metabolism 58 (2009), 1536–1542.
20. [20] Dewailly, EE, Blanchet, C, Gingras, S, Lemieux, S, Sauvé, L, Bergeron, J, et al. Relations between n-3 fatty acid status and cardiovascular disease risk factors among Quebecers. Am J Clin Nutr 74 (2001), 603–611.
21. [21] Stark, KD, Holub, BJ, Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr 79 (2004), 765–773.
22. [22] Grimsgaard, S, Bonaa, KH, Hansen, JB, Nordoy, A, Highly purified eicosapentaenoic acid and docosahexaenoic acid in human have similar triacylglycerol-lowering effects but divergent effects on fatty acids. Am J Clin Nutr 66 (1997), 649–659.
23. [23] Mori, TA, Burke, V, Puddey, IB, Watts, GF, O'Neal, DN, Best, JD, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71 (2000), 1085–1094.
24. [24] Nestel, P, Shige, H, Cehun, M, Abbey, M, Raederstorff, The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase arterial compliance in humans. Am J Clin Nutr 76 (2002), 326–330.
25. [25] Park, Y, Harris, WS, Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 44 (2003), 455–463.
26. [26] Woodman, RJ, Mori, TA, Burke, V, Puddey, IB, Barden, A, Watts, GF, et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic subjects. Atherosclerosis 166 (2003), 85–93.
27. [27] Eggert, S, Kannenberg, F, Somoza, V, Erbersdobler, HF, Wahrburg, U, Dietary α-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr 139 (2009), 861–868.
28. [28] Fekete, K, Marosvölgyi, T, Jakobik, V, Decsi, T, Methods of assessment of n–3 long-chain polyunsaturated fatty acid status in humans: a systematic review. Am J Clin Nutr 89 (2009), 2070S–2084S.
29. [29] Arterburn, LM, Hall, EB, Oken, H, Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83 (2006), 1467S–1476S [Suppl].
30. [30] Brenna, JT, Salem, N, Sinclair, AJ, Cunnane, SC, Alpha-linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 80 (2009), 85–91.
31. [31] Wada, M, DeLong, CJ, Hong, YH, Rieke, CH, Song, I, Sidhu, RS, et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 282 (2007), 22254–22266.
32. [32] Braeckman, RA, Manku, MS, Bays, HE, Stirtan, WG, Soni, PN, Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukot Essent Fatty Acids 89 (2013), 195–201.
33. [33] Davidson, MH, Maki, KC, Kalkowski, J, Schaefer, EJ, Torri, S, Drennan, K, Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr 16 (1997), 236–243.
34. [34] Berson, EL, Rosner, B, Sandberg, MA, Weigel-DiFranco, C, Moser, A, Brockhurst, RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin a treatment. Arch Ophthalmol 122 (2004), 1297–1305.
35. [35] Ooi, EMM, Lichtenstein, AH, Millar, JS, Diffenderfer, MR, Lamon-Fava, S, Rasmussen, H, et al. Effects of therapeutic lifestyle change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects. J Lipid Res 53 (2012), 1958–1967.
36. [36] Meydani, SN, Lichtenstein, AH, Cornwall, S, Meydani, M, Goldin, BR, Rasmussen, H, et al. Immunologic effects of National Cholesterol Education Panel step-2 diets with and without fish-derived N-3 fatty acid enrichment. J Clin Invest 92 (1993), 105–113.
37. [37] Mori, TA, Woodman, RJ, Burke, V, Puddey, IB, Croft, KD, Beilin, LJ, Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35 (2003), 772–781.
38. [38] Endres, S, Ghorbani, R, Kelley, V, Georgilis, K, Lonnemann, G, van der Meer, JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320 (1989), 265–271.
39. [39] Thompson, A, Danesh, J, Gao, P, Orfei, L, Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375 (2010), 1536–1544.
40. [40] Schmidt, EB, Koenig, W, Khuseyinova, N, Christensen, JH, Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis 196 (2008), 420–424.
41. 2 in healthy adults. Eur J Nutr 48 (2009), 1–5.
42. [42] Steffen, BT, Steffen, LM, Liang, S, Tracy, R, Jenny, NS, Tsai, MY, N-3 and n-6 fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the multi-ethnic study of atherosclerosis. Br J Nutr. 110 (2013), 1664–1671.
43. [43] Nelson, TL, Hokanson, JE, Hickey, MS, Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females. Eur J Nutr 50 (2011), 185–193.
44. [44] Brinton, EA, Ballantyne, CM, Bays, HE, Kastelein, JJ, Braeckman, RA, Soni, PN, Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol., 12, 2013, 100.
45. [45] Serhan, CN, Chiang, N, Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 153:Suppl. (2008), S200–S215.
46. [46] Gillies, PJ, Bhatia, SK, Belcher, LA, Hannon, DB, Thompson, JT, Vanden Heuvel, JP, Regulation of inflammatory and lipid metabolism genes by eicosapentaenoic acid-rich oil. J Lipid Res 53 (2012), 1679–1689.
47. [47] Tsunoda, F, Lamon-Fava, S, Asztalos, BF, Iyer, LK, Richardson, K, Schaefer, EJ, Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression. Atherosclerosis 241 (2015), 400–408.
48. [48] Estruch, R, Ros, E, Salas-Salvadó, J, Covas, MI, Corella, D, Arós, F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368 (2013), 1279–1290.